[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Emergent Biosolutions (EBS)

Emergent Biosolutions (EBS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 247,136
  • Shares Outstanding, K 51,273
  • Annual Sales, $ 742,900 K
  • Annual Income, $ 52,600 K
  • EBIT $ 13 M
  • EBITDA $ 118 M
  • 60-Month Beta 2.35
  • Price/Sales 0.34
  • Price/Cash Flow 1.27
  • Price/Book 0.70

Options Overview Details

View History
  • Implied Volatility 109.97% (+50.15%)
  • Historical Volatility 110.40%
  • IV Percentile 85%
  • IV Rank 19.91%
  • IV High 348.73% on 03/18/26
  • IV Low 50.62% on 01/16/26
  • Expected Move (DTE 28) 0.60 (12.34%)
  • Put/Call Vol Ratio 0.09
  • Today's Volume 244
  • Volume Avg (30-Day) 299
  • Put/Call OI Ratio 0.23
  • Today's Open Interest 12,180
  • Open Int (30-Day) 10,761
  • Expected Range 4.23 to 5.42

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.75
  • Number of Estimates 1
  • High Estimate $-0.75
  • Low Estimate $-0.75
  • Prior Year $1.06
  • Growth Rate Est. (year over year) -170.75%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.36 +12.39%
on 08/10/26
7.73 -36.61%
on 07/22/26
-2.75 (-35.95%)
since 07/21/26
3-Month
4.36 +12.39%
on 08/10/26
9.40 -47.87%
on 05/28/26
-3.47 (-41.46%)
since 05/21/26
52-Week
4.36 +12.39%
on 08/10/26
14.06 -65.15%
on 01/07/26
-4.42 (-47.42%)
since 08/21/25

Most Recent Stories

More News
Emergent BioSolutions Inc. (EBS) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

Law Offices of Howard G. Smith announces an investigation on behalf of Emergent BioSolutions Inc. (“Emergent BioSolutions” or the “Company”) (NYSE: EBS ) investors concerning the...

EBS : 4.96 (+2.90%)
Securities Fraud Investigation Into Emergent BioSolutions Inc. (EBS) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

The Law Offices of Frank R. Cruz announces an investigation of Emergent BioSolutions Inc. (“Emergent BioSolutions” or the “Company”) (NYSE: EBS ) on behalf of investors concerning...

EBS : 4.96 (+2.90%)
EBS Investors Have Opportunity to Join Emergent BioSolutions Inc. Fraud Investigation with SBS Law

Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Emergent BioSolutions Inc. (“Emergent”...

EBS : 4.96 (+2.90%)
Emergent BioSolutions (EBS) Securities Investigation Notice - Levi & Korsinsky

Emergent BioSolutions reported approximately $97 million in adjusted EBITDA for the quarter. The same period included a $191.3 million non-cash NARCAN impairment. Levi & Korsinsky is investigating potential...

EBS : 4.96 (+2.90%)
EBS Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Emergent BioSolutions (EBS)

Emergent BioSolutions shares dropped after the Company recorded a $191.3 million non-cash NARCAN impairment tied to naloxone competition and pricing pressure. Levi & Korsinsky is investigating potential...

EBS : 4.96 (+2.90%)
EBS SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Emergent BioSolutions

Emergent BioSolutions cut its FY2026 adjusted EBITDA outlook to $130-$150 million from $155-$175 million  amid continued NARCAN pricing and margin pressure, with NARCAN gross margin having fallen to...

EBS : 4.96 (+2.90%)
Emergent BioSolutions Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Emergent BioSolutions (EBS)

Emergent BioSolutions cut FY2026 revenue guidance to $645-$675 million after reaffirming a $720-$760 million outlook three months earlier. Levi & Korsinsky is investigating potential securities law violations....

EBS : 4.96 (+2.90%)
Emergent Biosolutions: Q2 Earnings Snapshot

Emergent Biosolutions: Q2 Earnings Snapshot

EBS : 4.96 (+2.90%)
Emergent BioSolutions Commits to Cross-Sector Collaboration Against Biological Threats in an Evolving Global Security Environment

GAITHERSBURG, Md., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE:EBS), a global biodefense company, today highlighted the increasing importance of biological threat preparedness as allied...

EBS : 4.96 (+2.90%)
Emergent BioSolutions Reports Second Quarter 2026 Financial Results

Second Quarter 2026 Total Revenues of $234.3 million, an improvement of 66% versus prior year Second Quarter 2026 Net Loss of $180.2 million worsening 1,402% versus prior year, largely due to a $191.3...

EBS : 4.96 (+2.90%)

Business Summary

Emergent BioSolutions, Inc. is a global specialty biopharmaceutical company offering specialized products to health care providers and governments to combat emerging public health threats. It also supplies vaccines to domestic and international non-government organizations and governments in/ outside...

See More

Key Turning Points

3rd Resistance Point 5.33
2nd Resistance Point 5.13
1st Resistance Point 4.98
Last Price 4.96
1st Support Level 4.62
2nd Support Level 4.42
3rd Support Level 4.27

See More

52-Week High 14.06
Fibonacci 61.8% 10.35
Fibonacci 50% 9.21
Fibonacci 38.2% 8.07
Last Price 4.96
52-Week Low 4.36

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.